Genmab Announces Financial Results for the First Half of 2023
3/8 17:01
August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023 Highlights EPKINLY™ (epcoritamab- bysp ) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody to treat adults with relapsed or refractory diffuse large...